Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2021

Open Access 01.12.2021 | Research article

Validation of evaluating left ventricular diastolic function with estimated left atrial volume from anteroposterior diameter

verfasst von: Yonghuai Wang, Liang Zhang, Shuang Liu, Guangyuan Li, Fanxin Kong, Cuiting Zhao, Jun Yang, Chunyan Ma

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2021

Abstract

Background

Left atrial (LA) volume (LAV) is one of the recommended key variables for evaluating left ventricular (LV) diastolic function. However, only LA anteroposterior diameter (LAAP) is available in numerous large-scale existing databases. Therefore, this study aimed to validate whether LV diastolic function could be evaluated with estimated LAV from LAAP.

Methods

A total of 552 inpatients with sinus rhythm were consecutively enrolled. LAV was measured by biplane Simpson’s disk summation method. LV diastolic function was evaluated according to the 2016 proposed recommendations. Best-fitting regression models of LAAP index (LAAPI)–LAV index (LAVI) were developed and equations with the highest F-value were chosen in the first 276 subjects (derivation set), and concordance for evaluating LV diastolic function between using estimated and observed LAVI was verified in the remaining 276 subjects (validation set).

Results

In the derivation set, the linear model has the highest F-value in all subjects and in the subjects with normal or depressed LV ejection fraction. In the validation set, using the linear equation (LAVI = 2.05 × LAAPI − 13.86), the higher area under curve and narrower range of difference were shown between estimated LAVI and observed LAVI, respectively. Further, concordance for diagnosis (overall proportion of agreement, 88.4%; κ = 0.79) and grading (overall proportion of agreement, 84.8%; κ = 0.74) of LV diastolic dysfunction was substantial between using estimated and observed LAVI.

Conclusions

LV diastolic function can be evaluated with estimated LAVI from LAAPI, which might provide a surrogate method when the direct measurement of LAV is not available.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
LV
Left ventricular
DD
Diastolic dysfunction
LVEF
Left ventricular ejection fraction
DF
Diastolic function
ASE
American Society of Echocardiography
EACVI
European Association of Cardiovascular Imaging
LA
Left atrial
LAV
Left atrial volume
LAAP
Left atrial anteroposterior diameter
TR
Tricuspid regurgitation
SD
Standard deviation
CI
Confidence interval
ROC
Receiver operating characteristic
AUC
Area under curve

Introduction

Left ventricular (LV) diastolic dysfunction (DD) is associated with an increase in all-cause mortality in the general population, even in the preclinical stage [1]. The presence of LVDD is a cardinal feature to diagnose heart failure with preserved LV ejection fraction (LVEF) [2, 3]. Therefore, an accurate evaluation of LV diastolic function (DF) is of pivotal importance in routine clinical settings.
Recently, the proposed recommendations by the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) in 2016 integrated two-dimensional echocardiographic and Doppler echocardiographic parameters and provided a practical and reliable algorithm for diagnosing and grading LVDD irrespective of LVEF [4]. Among these parameters, left atrial (LA) volume index (LAVI) is the recommended key two-dimensional variable for evaluating LVDF. However, LAV is not available in numerous early study designs, such as the preliminary stage of Framingham Heart Study [5, 6], the Strong Heart Study [7], the Jackson Heart Study [8], and others, or even in several current large-scale cross-sectional analysis [9], which has precluded retrospective analyses of large-scale existing databases related to LVDF.
Although the LAV measured using the biplane disk summation algorithm is more accurate and recommended to describe LA size in routine clinical practice and research [10, 11], LA anteroposterior diameter (LAAP) is present extensively in plenty of large-scale databases or trials because it is relatively more readily available and has better measurement reproducibility than LAV [1214]. However, whether LAVI can be estimated from LAAP index (LAAPI) and then be used for evaluating LVDF when the direct measurement of LAV is no available is still not well understood.
In view of the foregoing considerations, we conducted this study to develop the best-fitting regression models and seek the optimum equations for estimating LAVI from LAAPI, and validate whether LVDF could be evaluated with estimated LAVI, which might provide a surrogate method to evaluate LVDF when the direct measurement of LAV is not available or the LAV values are highly variable.

Material and methods

Study population

We prospectively and consecutively enrolled the inpatients in sinus rhythm from the Cardiology Department of our hospital from January 2019 to October 2019.
In accordance with the 2016 recommendations for the evaluation of LVDF from the ASE and EACVI [4], patients with specific cardiovascular disease in which the evaluating algorithm had significant limitations were excluded, such as the patients with atrial fibrillation, sinus tachycardia, atrioventricular block, left bundle branch block, hypertrophic and restrictive cardiomyopathy, significant mitral annular calcification, mitral stenosis, moderate and severe mitral regurgitation, severe aortic regurgitation, noncardiac pulmonary hypertension, right ventricular pacing, cardiac resynchronization therapy, valvular heart surgery or intervention and heart transplantation. Moreover, to obtain accurate measurements of LAV and LAAP, patients with poor quality of echocardiography, hyper-mobile interatrial septum or interatrial septal aneurysm, dilated aortic root or ascending aortic encroaching on the LA anterior wall, dilated or tortuous descending aorta indenting the LA posterior wall, and severe calcification at aortic sinuses and aortic valve were also excluded from this study.
A total of 552 subjects (mean age 58.4 ± 11.1 years, 221 women) met the eligibility criteria during the study period. These subjects were randomly divided into two groups: (1) derivation set (n = 276, mean age 59.1 ± 10.8 years, 114 women), in which best-fitting regression models and equations of LAVI–LAAPI were developed; and (2) validation set (n = 276, mean age 57.7 ± 11.3 years, 107 women), in which concordance for evaluating LVDF between using estimated and observed LAVI was verified.
Written informed consent was obtained from all patients before enrollment. The study protocol was approved by the China Medical University Ethics Committee and was conducted in line with the ethical guidelines of the 1975 Declaration of Helsinki.

Echocardiography

All subjects were examined at rest using a Vivid E9 ultrasound system (GE Healthcare, Waukesha, WI, USA) equipped with M5S phased-array probe. Standard two-dimensional cine loops, including at least 3 consecutive cardiac cycles, and Doppler spectrum during normal respiration (< 20 breaths/min) were recorded for offline analysis using an EchoPAC workstation (GE Healthcare). Both image acquisition and quantitative analysis were performed according to the recommendations of transthoracic echocardiographic examination and cardiac chamber quantification from ASE by two experienced cardiologists who were blinded to any clinical data [15, 16].
LVEF was measured using the biplane Simpson’s disk summation method from both the apical two- and four-chamber views during LV end-diastole. LVEF < 52% in males or < 54% in females was considered depressed [15]. LAAP was measured during LV end-systole from the parasternal long-axis view [15]. LAV was measured using the biplane Simpson’s disk summation method from both the apical two- and four-chamber views during LV end-systole (Fig. 1). LAVI and LAAPI were LAV and LAAP divided by body surface area, respectively. Mitral inflow early diastolic (E) and late diastolic (A) peak velocity by pulsed flow Doppler, the septal and lateral early diastolic mitral annulus peak velocity (e′) by pulsed tissue Doppler, and tricuspid regurgitation (TR) systolic jet velocity by continuous Doppler were measured in the apical four-chamber views. Then E/A, average e′ and average E/e′ were calculated.
The diagnosis and grading of LVDD was performed according to 2016 ASE/EACVI recommendations [4]. For patients with normal LVEF, four variables were recommended for diagnosing LVDD (septal e′ < 7 cm/s or lateral e′ < 10 cm/s, average E/e′ > 14, LAVI > 34 mL/m2, TR velocity > 2.8 m/s). Patients were diagnosed with normal DF if none or only one variable met the cutoff values, DD if more than two of the variables met the cutoff values, and indeterminate if just two variables met the cutoff values. In patients with normal LVEF and myocardial disease or DD, and in those with depressed LVEF, grade I DD was diagnosed if E/A ratio ≤ 0.8 and E ≤ 50 cm/s and grade III DD if E/A ratio ≥ 2. If E/A ≤ 0.8 and E > 50 cm/s, or 0.8 < E/A < 2, additional variables are needed (average E/e′ > 14, LAVI > 34 mL/m2, TR velocity > 2.8 m/s). Grade I DD was diagnosed if only one of the variables met the cutoff values, and grade II DD if more than two of the variables met the cutoff values. However, if only one variable is available, or only two variables are available but discrepant, LV diastolic dysfunction grade could not be determined.

Reproducibility

Inter- and intra-observer agreement of LAAP and LAV measurements were examined in 10 randomly selected patients. To assess intra-observer variability, the same doctor repeated the measurements after > 4 weeks. In addition, to assess inter-observer variability, the two doctors independently repeated the measurements twice.

Statistical analysis

Statistical analyses were performed using SPSS version 21.0 statistical software (IBM Corp, Armonk, NY) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Normality plots with tests were performed using the Shapiro–Wilk test. Continuous data were expressed as mean ± standard deviation (SD) or median (interquartile range), and categorical variables as numbers and percentages. In the comparison between derivation set and validation set, differences in continuous variables were assessed by independent samples t-test or Mann–Whitney U test where appropriate, and categorical variables by chi-square test or Fisher exact test. Correlation between LAVI and LAAPI was sought using Pearson correlation analyses. In the derivation set, the best-fitting regression models between LAVI and LAAPI were developed, including linear, logarithmic, quadratic, cubic, compound, power, S, growth, and exponential. The F-values, which express the statistical significance of the different models, of these models were compared. The regression equations with the highest F-values were chosen to calculate the estimated LAVI in the validation set. The comparison between the observed LAVI with estimated LAVI by each equation was performed by paired samples t-test or Wilcoxon test, where appropriate. The variability of estimated and observed LAVI was assessed by calculating the intra-class correlation coefficient and 95% confidence interval (CI) using a two-way random-effects model. Receiver operating characteristic (ROC) curve analysis and area under curve (AUC) were used to evaluate the performance for identifying observed LAVI > 34 mL/m2. Bland–Altman analyses were used for assessing the bias and limits of agreement (LOA) between the observed and estimated LAVI, and estimating the inter-observer and intra-observer reproducibility of LAAP and LAV. The concordance for evaluating LV diastolic function between using estimated and observed LAVI were tested by calculating the κ coefficient and the overall proportion of agreement (proportion of subjects identically classified). The calculated κ coefficient was judged as follows: 0 ≤ κ < 0.2 slight; 0.2 ≤ κ < 0.4 fair; 0.4 ≤ κ < 0.6 moderate; 0.6 ≤ κ < 0.8 substantial, and 0.8 ≤ κ < 1 perfect [17].

Results

The demographic characteristics and echocardiographic measurements of the population in the derivation and validation sets are listed in Table 1. There were no significant differences in age, sex, body surface area, and heart rate between the groups (P > 0.05 for all). There were similar prevalence rates between the groups in depressed LVEF, LAVI > 34 mL/m2, septal e′ velocity < 7 cm/s, lateral e′ velocity < 10 cm/s, average E/e′ > 14, and TR velocity > 2.8 m/s (P > 0.05 for all).
Table 1
Demographic characteristics and echocardiographic measurements of the population
Variable
Derivation set (n = 276)
Validation set (n = 276)
P value
Age (years)
59.1 ± 10.8
57.7 ± 11.3
0.13
Female [n (%)]
114 (41.3%)
107 (38.8%)
0.52
Body surface area (m2)
1.76 ± 0.17
1.78 ± 0.18
0.40
Heart rate (bpm)
69.1 ± 12.5
69.7 ± 11.9
0.60
LV end-diastolic diameter (mm)
53.11 ± 8.74
52.99 ± 8.54
0.87
LV end-diastolic volume (mL)
94.00 (78.00–122.00)
97.00 (79.25–127.00)
0.69
LVEF (%)
56.69 ± 12.12
56.86 ± 12.13
0.87
Depressed LVEF [n (%)]
59 (21.4%)
60 (21.7%)
0.92
LAAP (mm)
39.44 ± 5.94
39.25 ± 6.21
0.72
LAAPI (mm/m2)
22.50 ± 3.68
22.20 ± 3.49
0.32
LAAPI > 23 mm/m2 [n (%)]
105 (38.0%)
89 (32.2%)
0.15
LAV (mL)
53.00 (43.00–66.83)
51.50 (42.00–67.00)
0.62
LAVI (mL/m2)
30.19 (24.16–36.73)
29.03 (23.59–37.13)
0.48
LAVI > 34 mL/m2 [n (%)]
94 (34.1%)
89 (32.2%)
0.65
Septal e′ velocity (cm/s)
6.09 ± 2.30
6.11 ± 2.49
0.92
Septal e′ velocity < 7 cm/s [n (%)]
168 (60.9%)
168 (60.9%)
1.00
Lateral e′ velocity (cm/s)
8.88 ± 3.31
8.70 ± 3.40
0.51
Lateral e′ velocity < 10 cm/s [n (%)]
163 (59.1%)
174 (63.0%)
0.36
Average E/e′
10.96 ± 5.54
11.24 ± 5.74
0.56
Average E/e′ > 14 [n (%)]
51 (18.5%)
54 (19.6%)
0.78
TR velocity > 2.8 m/s [n (%)]
37/214
35/229
0.57
Values shown are mean ± SD, median (interquartile range), or frequency (percentages)
LV left ventricle, LVEF left ventricular ejection fraction, LAAP left atrial anteroposterior diameter, LAAPI left atrial anteroposterior diameter index, LAV left atrial volume, LAVI left atrial volume index, e′ early diastolic annular peak velocity, E early diastolic flow peak velocity, TR tricuspid regurgitation

Analysis in derivation set

There was a significant correlation between LAVI and LAAPI (r = 0.67, P < 0.001), and the correlation coefficient between LAVI and LAAPI in the subjects with depressed LVEF (r = 0.68, P < 0.001) was larger than that in subjects with normal LVEF (r = 0.53, P < 0.001) (Fig. 2).
Table 2 displays the best-fitting regression models for computation of LAVI from LAAPI in derivation set. The linear model had the highest F-value in all subjects (r2 = 0.44, F = 218.60, P < 0.001) and in the subjects with normal or depressed LVEF (r2 = 0.28, F = 83.06, P < 0.001; r2 = 0.46, F = 48.65, P < 0.001). Therefore, we estimated LAVI from LAAPI stratified by LVEF using two regression equations (first equation: LAVI = 2.05 × LAAPI − 13.86 in all subjects; second equation: LAVI = 1.54 × LAAPI − 3.97 in the subjects with normal LVEF and LAVI = 2.15 × LAAPI − 12.83 in the subjects with depressed LVEF).
Table 2
Best-fitting regression models for computation of LAVI from LAAPI in the derivation set
Equation
r2
F
P value
Constant
β1
β2
β3
All subjects (n = 276)
       
 Linear
0.44
218.60
< 0.001
− 13.86
2.05
  
 Logarithmic
0.42
202.20
< 0.001
− 112.93
46.80
  
 Quadratic
0.45
113.70
< 0.001
19.75
− 0.82
0.06
 
 Cubic
0.45
113.83
< 0.001
13.77
0.00
0.02
0.0005
 Compound
0.40
182.78
< 0.001
8.55
1.06
  
 Power
0.40
181.13
< 0.001
0.51
1.32
  
 S
0.39
173.69
< 0.001
4.75
− 29.29
  
 Growth
0.40
182.78
< 0.001
2.15
0.06
  
 Exponential
0.40
182.78
< 0.001
8.55
0.06
  
Subjects with normal LVEF (n = 217)
       
 Linear
0.28
83.06
< 0.001
− 3.97
1.54
  
 Logarithmic
0.28
82.80
< 0.001
− 74.53
33.92
  
 Quadratic
0.28
41.42
< 0.001
− 10.77
2.16
− 0.01
 
 Cubic
0.28
41.43
< 0.001
− 8.77
1.87
0.00
− 0.0002
 Compound
0.27
78.31
< 0.001
9.84
1.05
  
 Power
0.27
81.37
< 0.001
1.00
1.09
  
 S
0.28
82.61
< 0.001
4.45
− 23.44
  
 Growth
0.27
78.31
< 0.001
2.29
0.05
  
 Exponential
0.27
78.31
< 0.001
9.84
0.05
  
Subjects with depressed LVEF (n = 59)
       
 Linear
0.46
48.65
< 0.001
− 12.83
2.15
  
 Logarithmic
0.45
45.92
< 0.001
− 131.36
53.79
  
 Quadratic
0.47
24.53
< 0.001
20.51
− 0.48
0.05
 
 Cubic
0.47
24.53
< 0.001
16.62
0.00
0.03
0.0002
 Compound
0.40
38.25
< 0.001
10.53
1.05
  
 Power
0.40
38.10
< 0.001
0.57
1.31
  
 S
0.39
37.00
< 0.001
4.97
− 32.05
  
 Growth
0.40
38.25
< 0.001
2.35
0.05
  
 Exponential
0.40
38.25
< 0.001
10.53
0.05
  
The bold values indicated the selected regression model for computation of LAVI from LAAPI
LVEF left ventricular ejection fraction, LAAPI left atrial anteroposterior diameter index, LAVI left atrial volume index

Analysis in validation set

Before estimating LAVI, we first analyzed the identifying performance of LAAPI for LAVI > 34 mL/m2 [AUC, 0.85 (0.80–0.90); P < 0.001], and the concordance between LAAPI > 23 mm/m2 with LAVI > 34 mL/m2 (overall proportion of agreement, 77.0%; κ = 0.47).
After estimating LAVI using the abovementioned two regression equations in the validation set, we compared the observed LAVI with estimated LAVI by each regression equation respectively, and found that there were no significant differences between the observed LAVI [29.03 (23.59–37.13) mL/m2] and estimated LAVI by the first equation [30.79 (26.88–35.42) mL/m2] and the second equation [29.98 (27.23–33.98) mL/m2] (Fig. 3).
Table 3 displays the intra-class correlations between estimated and observed LAVI, identifying performance of estimated LAVI for observed LAVI > 34 mL/m2, and concordance between estimated and observed LAVI > 34 mL/m2, respectively. The estimated LAVI using the first equation showed the similar intra-class correlations coefficient [ρ, 0.63 (0.55–0.70); P < 0.001] and overall proportion of agreement (78.98%) with observed LAVI, but the slightly higher AUC [0.85 (0.80–0.90); P < 0.001] for identifying observed LAVI > 34 mL/m2. In Bland–Altman analysis, the estimated LAVI using the first equation showed the slightly narrower range of difference compared with observed LAVI (Fig. 4). Therefore, we finally used the first equation to estimate LAVI from LAAPI and further evaluate LVDF.
Table 3
Relationship between observed and estimated LAVI in the validation set
 
Equation 1
Equation 2
Intra-class correlationsa
  
 Coefficient (95% CI)
0.63 (0.55–0.70)
0.63 (0.55–0.70)
 P value
< 0.001
< 0.001
ROC analysesb
  
 Area under curve (95% CI)
0.85 (0.80–0.90)
0.84 (0.79–0.89)
 P value
< 0.001
< 0.001
Concordance testc
  
 κ coefficient
0.50
0.49
 Overall proportion of agreement
78.98%
78.98%
Bland–Altman analyses
  
 Mean difference
− 0.02
− 0.02
 Limits of agreement
− 14.73 to 14.68
− 14.80 to 14.76
LAVI left atrial volume index, ROC receiver operating characteristic, CI confidence interval
aIntra-class correlations between observed and estimated LAVI
bIdentifying performance of estimated LAVI for observed LAVI > 34 mL/m2
cConcordance between observed and estimated > 34 mL/m2
Concordance for diagnosis (overall proportion of agreement, 88.4%; κ = 0.79) and grading (overall proportion of agreement, 84.8%; κ = 0.74) of LVDD was substantial between using estimated and observed LAVI (Table 4 and Fig. 5). The overall reclassification rate was 15.2% (42 patients). Seven patients (2.5%) had normal DF according to observed LAVI but indeterminate on the basis of estimated LAVI. One patient (0.4%) and 9 patients (3.3%) with grade I DD according to observed LAVI were reclassified to normal DF and grade II DD using estimated LAVI, respectively. One patient (0.4%) and 3 patients (1.1%) with grade II DD according to observed LAVI were reclassified to grade I DD and indeterminate according to estimated LAVI. And Seventeen patients (6.2%) and 4 patients (1.4%) with indeterminate according to observed LAVI were reclassified to normal DF and grade II DD using estimated LAVI, respectively.
Table 4
Reclassification cross-relations for diagnosis and grading of LV DD between using estimated and observed LAVI
 
Using observed LAVI
 
Normal DF
Grade I DD
Grade II DD
Grade III DD
Indeterminate
Total
Using estimated LAVI
      
 Normal DF
155
1
0
0
17
173
 Grade I DD
0
23
1
0
0
24
 Grade II DD
0
9
20
0
4
33
 Grade III DD
0
0
0
17
0
17
 Indeterminate
7
0
3
0
19
29
 Total
162
33
24
17
40
276
LV left ventricle, DD diastolic dysfunction, LAVI left atrial volume index, DF diastolic function

Reproducibility

Inter-observer and intra-observer reproducibility for LAAP and LAV was high. The inter-observer reproducibility for LAAP and LAV had a bias of 0.5 mm (LOA, − 0.5 to 1.4 mm), and 0.6 mL (LOA, − 5.3 to 6.4 mL), respectively. The intra-observer reproducibility for LAAP and LAV had a bias of − 0.1 mm (LOA, − 1.1 to 0.9 mm), and 0.6 mL (LOA, − 4.7 to 5.8 mL), respectively.

Discussion

In the present study, we developed the best-fitting regression models for estimating LAVI from LAAPI and established the optimum linear regression equations in the subjects with normal LVEF and depressed LVEF in the derivation set, respectively. We also validated that LVDF could be evaluated with estimated LAVI from LAAPI in the validation set when the direct measurement of LAV is not available or the LAV values are highly variable.
Normal LVDF plays a significant role in ensuring normal LV filling and adequate cardiac output. LVDD has been recognized to be associated with incident heart failure and resultant poor outcomes [18, 19], and even related to a marked increase of all-cause mortality in the general population [1]. Therefore, the accurate evaluation of LVDF is increasingly becoming an essential element in routine clinical settings. Among imaging techniques to evaluate LVDF, echocardiography has become a widely used and powerful tool for diagnosing LVDD as well as further tracking of pathological changes and even making clinical decision on a day-to-day basis [20, 21].
LA size is one of the recommended indispensable elements for evaluating LVDF by echocardiography as per recommendations from ASE and EACVI because it can reflect the chronicity and severity of LVDD [4]. To describe LA size, LAV is the preferred method over LA diameter since LA dilation in each dimension may not be uniform due to the physical confinement of the adjacent structure [22, 23]. That notwithstanding, LAAP is widely used in routine practice or a multicenter setting, and is present extensively in numerous large databases or trials because it is relatively more readily available and has better measurement reproducibility than LAV [24, 25]. In this study, we validated that LVDF also could be evaluated with estimated LAVI from LAAPI when the direct measurement of LAV is not available. However, our most noteworthy objective is to provide a surrogate to evaluate LVDF when the directly measured LAV is not available on retrospective analysis of the older existing large-scale databases, rather than directly substituting the recommended algorithm for diagnosing and grading of LVDD from ASE and EACVI.
Maybe, it was an optimistic thinking that LAAPI > 23 mm/m2 could be directly substituted as a variable for LAVI > 34 mL/m2 to assess LV DF when directly measured LAV is not available. However, our study revealed that the concordance between LAAPI > 23 mm/m2 with LAVI > 34 mL/m2 were lower than the estimated LAVI obtained by the proposed regression equation in our study. Therefore, our results indicated that this optimistic idea was not recommended when directly measured LAV is unavailable.
Recently, Canciello et al. [26] developed regression models to compute LAV by the biplane Simpson’s disk summation method, area-length method, and elliptical method from LAAP respectively in the derivation series including 70 subjects and reported that LAV by elliptical method can be predicted with good accuracy by simple measurement of LAAP using a nonlinear equation. However, the elliptical method may be more susceptible to geometric assumptions about LA shape and thus may underestimate the actual LAVI and hinder the accurate definition of LA dilatation [27, 28]. Notably, our study established the optimum regression equations for estimating LAVI by biplane Simpson’s disk summation method, as recommended by ASE and EACVI in routine clinical practice, in a larger sample size. Moreover, our study further validated that the estimated LAVI could also be used to evaluate LVDF, which might provide a surrogate method to evaluate LVDF when the direct measurement of LAV is not available or the LAV values are highly variable. Because the ASE recommendation is universal, our results may also be applicable for the other ethnicities and races, and may also provide a valuable reference for the clinicians in different regions, although our study was based on the Chinese population whose LA size may be different from other ethnic or racial populations.

Limitations

The major limitation of our study was related to the exclusion of the patients with several specific cardiovascular diseases, such as atrial fibrillation, mitral valve dysfunction, left bundle branch block, hypertrophic cardiomyopathy, and so on, in which the evaluation of LVDF required the determination of additional specific parameters according to the 2016 recommendations [4]. This may limit the generalizability of our findings in these patients.
Another study limitation was the relatively low percentage of patients with depressed LVEF and limited range of LAVI, which was mainly attributable to the unselected and consecutively recruited population for reducing selection bias in the present study, and a multicenter study with a larger number of patients with depressed LVEF and a wide range of LAVI should be designed to verify the findings.

Conclusions

LVDF can be evaluated with estimated LAVI from LAAPI, which might provide a surrogate method when the direct measurement of LAV is not available or the LAV values are highly variable. It is necessary to verify these results in future practice.

Acknowledgements

We thank Editage for English language review.
Written informed consent was obtained from all patients before enrollment. The study protocol was approved by the China Medical University Ethics Committee and was conducted in line with the ethical guidelines of the 1975 Declaration of Helsinki.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.CrossRef Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194–202.CrossRef
2.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.
3.
Zurück zum Zitat Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858–73.CrossRef Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O’Meara E, Ryan JJ, et al. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858–73.CrossRef
4.
Zurück zum Zitat Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.CrossRef Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.CrossRef
5.
Zurück zum Zitat Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. Framingham Heart Study Circ. 1995;92(4):835–41.CrossRef Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. Framingham Heart Study Circ. 1995;92(4):835–41.CrossRef
6.
Zurück zum Zitat Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. Framingham Heart Study Hypertens. 1995;25(6):1155–60. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. Framingham Heart Study Hypertens. 1995;25(6):1155–60.
7.
Zurück zum Zitat Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, Roman MJ, Devereux RB. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). Am Heart J. 2006;151(2):412–8.CrossRef Kizer JR, Bella JN, Palmieri V, Liu JE, Best LG, Lee ET, Roman MJ, Devereux RB. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS). Am Heart J. 2006;151(2):412–8.CrossRef
8.
Zurück zum Zitat Liu J, Fox CS, Hickson DA, May WL, Ding J, Carr JJ, Taylor HA. Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diabetes Care. 2011;34(2):341–6.CrossRef Liu J, Fox CS, Hickson DA, May WL, Ding J, Carr JJ, Taylor HA. Pericardial fat and echocardiographic measures of cardiac abnormalities: the Jackson Heart Study. Diabetes Care. 2011;34(2):341–6.CrossRef
9.
Zurück zum Zitat Boraita A, Santos-Lozano A, Heras ME, Gonzalez-Amigo F, Lopez-Ortiz S, Villacastin JP, Lucia A. Incidence of atrial fibrillation in elite athletes. JAMA Cardiol. 2018;3(12):1200–5.CrossRef Boraita A, Santos-Lozano A, Heras ME, Gonzalez-Amigo F, Lopez-Ortiz S, Villacastin JP, Lucia A. Incidence of atrial fibrillation in elite athletes. JAMA Cardiol. 2018;3(12):1200–5.CrossRef
10.
Zurück zum Zitat Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(15):1961–77.CrossRef Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(15):1961–77.CrossRef
11.
Zurück zum Zitat Vyas H, Jackson K, Chenzbraun A. Switching to volumetric left atrial measurements: impact on routine echocardiographic practice. Eur J Echocardiogr. 2011;12(2):107–11.CrossRef Vyas H, Jackson K, Chenzbraun A. Switching to volumetric left atrial measurements: impact on routine echocardiographic practice. Eur J Echocardiogr. 2011;12(2):107–11.CrossRef
12.
Zurück zum Zitat Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, Kimball TR, Towbin JA, Malik P, Taylor MD. Cardiomyopathy with restrictive physiology in sickle cell disease. JACC Cardiovasc Imaging. 2016;9(3):243–52.CrossRef Niss O, Quinn CT, Lane A, Daily J, Khoury PR, Bakeer N, Kimball TR, Towbin JA, Malik P, Taylor MD. Cardiomyopathy with restrictive physiology in sickle cell disease. JACC Cardiovasc Imaging. 2016;9(3):243–52.CrossRef
13.
Zurück zum Zitat Froehlich L, Meyre P, Aeschbacher S, Blum S, Djokic D, Kuehne M, Osswald S, Kaufmann BA, Conen D. Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis. Heart. 2019;105(24):1884–91.CrossRef Froehlich L, Meyre P, Aeschbacher S, Blum S, Djokic D, Kuehne M, Osswald S, Kaufmann BA, Conen D. Left atrial dimension and cardiovascular outcomes in patients with and without atrial fibrillation: a systematic review and meta-analysis. Heart. 2019;105(24):1884–91.CrossRef
14.
Zurück zum Zitat Iskandar A, Mujtaba MT, Thompson PD. Left atrium size in elite athletes. JACC Cardiovasc Imaging. 2015;8(7):753–62.CrossRef Iskandar A, Mujtaba MT, Thompson PD. Left atrium size in elite athletes. JACC Cardiovasc Imaging. 2015;8(7):753–62.CrossRef
15.
Zurück zum Zitat Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.CrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.CrossRef
16.
Zurück zum Zitat Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1–64.CrossRef Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA, Velazquez EJ. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32(1):1–64.CrossRef
17.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRef
18.
Zurück zum Zitat Kosmala W, Marwick TH. Asymptomatic left ventricular diastolic dysfunction: predicting progression to symptomatic heart failure. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):215–27.CrossRef Kosmala W, Marwick TH. Asymptomatic left ventricular diastolic dysfunction: predicting progression to symptomatic heart failure. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):215–27.CrossRef
19.
Zurück zum Zitat Prasad SB, Lin AK, Guppy-Coles KB, Stanton T, Krishnasamy R, Whalley GA, Thomas L, Atherton JJ. Diastolic dysfunction assessed using contemporary guidelines and prognosis following myocardial infarction. J Am Soc Echocardiogr. 2018;31(10):1127–36.CrossRef Prasad SB, Lin AK, Guppy-Coles KB, Stanton T, Krishnasamy R, Whalley GA, Thomas L, Atherton JJ. Diastolic dysfunction assessed using contemporary guidelines and prognosis following myocardial infarction. J Am Soc Echocardiogr. 2018;31(10):1127–36.CrossRef
20.
Zurück zum Zitat Nagueh SF. Left ventricular diastolic function: understanding pathophysiology, diagnosis, and prognosis with echocardiography. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):228–44.CrossRef Nagueh SF. Left ventricular diastolic function: understanding pathophysiology, diagnosis, and prognosis with echocardiography. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):228–44.CrossRef
21.
Zurück zum Zitat Silbiger JJ. Pathophysiology and echocardiographic diagnosis of left ventricular diastolic dysfunction. J Am Soc Echocardiogr. 2019;32(2):216-232 e2.CrossRef Silbiger JJ. Pathophysiology and echocardiographic diagnosis of left ventricular diastolic dysfunction. J Am Soc Echocardiogr. 2019;32(2):216-232 e2.CrossRef
22.
Zurück zum Zitat Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol. 1999;84(7):829–32.CrossRef Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol. 1999;84(7):829–32.CrossRef
23.
Zurück zum Zitat Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. 2003;41(6):1036–43.CrossRef Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. 2003;41(6):1036–43.CrossRef
24.
Zurück zum Zitat Olshansky B, Heller EN, Mitchell LB, Chandler M, Slater W, Green M, Brodsky M, Barrell P, Greene HL. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005;45(12):2026–33.CrossRef Olshansky B, Heller EN, Mitchell LB, Chandler M, Slater W, Green M, Brodsky M, Barrell P, Greene HL. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005;45(12):2026–33.CrossRef
25.
Zurück zum Zitat Rusinaru D, Tribouilloy C, Grigioni F, Avierinos JF, Suri RM, Barbieri A, Szymanski C, Ferlito M, Michelena H, Tafanelli L, et al. Left atrial size is a potent predictor of mortality in mitral regurgitation due to flail leaflets: results from a large international multicenter study. Circ Cardiovasc Imaging. 2011;4(5):473–81.CrossRef Rusinaru D, Tribouilloy C, Grigioni F, Avierinos JF, Suri RM, Barbieri A, Szymanski C, Ferlito M, Michelena H, Tafanelli L, et al. Left atrial size is a potent predictor of mortality in mitral regurgitation due to flail leaflets: results from a large international multicenter study. Circ Cardiovasc Imaging. 2011;4(5):473–81.CrossRef
26.
Zurück zum Zitat Canciello G, de Simone G, Izzo R, Giamundo A, Pacelli F, Mancusi C, Galderisi M, Trimarco B, Losi MA. Validation of left atrial volume estimation by left atrial diameter from the parasternal long-axis view. J Am Soc Echocardiogr. 2017;30(3):262–9.CrossRef Canciello G, de Simone G, Izzo R, Giamundo A, Pacelli F, Mancusi C, Galderisi M, Trimarco B, Losi MA. Validation of left atrial volume estimation by left atrial diameter from the parasternal long-axis view. J Am Soc Echocardiogr. 2017;30(3):262–9.CrossRef
27.
Zurück zum Zitat Aurigemma GP, Gottdiener JS, Arnold AM, Chinali M, Hill JC, Kitzman D. Left atrial volume and geometry in healthy aging: the Cardiovascular Health Study. Circ Cardiovasc Imaging. 2009;2(4):282–9.CrossRef Aurigemma GP, Gottdiener JS, Arnold AM, Chinali M, Hill JC, Kitzman D. Left atrial volume and geometry in healthy aging: the Cardiovascular Health Study. Circ Cardiovasc Imaging. 2009;2(4):282–9.CrossRef
28.
Zurück zum Zitat Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). Am J Cardiol. 2006;97(1):83–9.CrossRef Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). Am J Cardiol. 2006;97(1):83–9.CrossRef
Metadaten
Titel
Validation of evaluating left ventricular diastolic function with estimated left atrial volume from anteroposterior diameter
verfasst von
Yonghuai Wang
Liang Zhang
Shuang Liu
Guangyuan Li
Fanxin Kong
Cuiting Zhao
Jun Yang
Chunyan Ma
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2021
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-01920-y

Weitere Artikel der Ausgabe 1/2021

BMC Cardiovascular Disorders 1/2021 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.